Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Roche's implant for chronic eye disorder wins U.S. approval

10/22/2021 | 05:41pm EST
FILE PHOTO: Coronavirus disease (COVID-19) outbreak in Lausanne

(Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments.

The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula.

The device is designed to continuously deliver a customized version of the Swiss company's drug ranibizumab, branded as Lucentis, which is an anti-vascular endothelial growth factor (anti-VEGF) therapy.

Anti-VEGF therapies, the current standard of care for wet AMD, work against a protein said to play a key role in the disease. They require patients to receive eye injections as often as monthly to preserve vision.

Susvimo is intended for those who have previously responded to at least two anti-VEGF injections and needs to be taken only twice a year, reducing the treatment burden for patients.

Roche said Susvimo, which includes the implanted device and medicine, would be priced at $9,250 for the first six months. Refills are priced at $8,000 for every six months.

More than 98% of patients treated with the device were able to go six months before needing a refill in the company's late-stage study last year.

"This device will be a first-of-its-kind alternative to the current standard of care injections for patients with wet AMD," Levi Garraway, Roche's chief medical officer, said in an interview with Reuters before the approval.

The device has an exchange mechanism that automatically refills a new batch of medicine while the residual drug is being removed, Garraway said.

UBS analyst Michael Leuchten estimates that the U.S. market size for AMD is roughly $3.5 billion.

Susvimo's approval comes with a warning that the implant was associated with a three-fold higher rate of eye infection endophthalmitis than monthly injections of Lucentis.

(Reporting by Amruta Khandekar and Bhanvi Satija; Editing by Aditya Soni and Maju Samuel)

By Amruta Khandekar and Bhanvi Satija


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -0.31% 73.57 Delayed Quote.-12.05%
REGENERON PHARMACEUTICALS 0.18% 635.16 Delayed Quote.31.23%
Latest news "Economy & Forex"
04:30aChina securities regulator says govt policies have no "necessary connection" with overseas IPOs
RE
04:23aBahrain central bank plans to offer digital Dinar - Sky News Arabia
RE
03:58aCHINA SECURITIES REGULATOR : Says has achieved positive progress in promoting cooperation on some key issues with sec and pcaob
RE
03:57aCHINA SECURITIES REGULATOR : Says has held candid, and constructive communications with sec and pcaob
RE
03:56aCHINA SECURITIES REGULATOR : Says chinese govt policies are not targeting specific industry or private companies, and has no connection with firms' overseas listing
RE
03:53aCHINA SECURITIES REGULATOR : Says it understands some domestic firms are actively communicating with domestic and overseas regulators to list in the u.s.
RE
03:51aCHINA SECURITIES REGULATOR : Says will continue to communicate with u.s. counterpart to resolve accounting and regulating issues
RE
03:50aCHINA SECURITIES REGULATOR : Says media report that china will ban companies with vie structure from u.s. listing is total misunderstanding and misreading
RE
03:48aCHINA SECURITIES REGULATOR : Says respects chinese companies' choice of listing venues on the basis of compliance
RE
03:32aECOWAS Mission Observes the Presidential Election in The Gambia
PU
Latest news "Economy & Forex"